PFE News 28.89 08/21/2014 05:30:27 Pfizer Inc (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 28.89 $PFE

Most active New York Stock Exchange-traded stocks
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:

Final Glance: Pharmaceuticals companies
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:

Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.

Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD

Midday Glance: Pharmaceuticals companies
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:

Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

Expanding IBD Research Through Collaboration
PR Newswire - Wed Aug 20, 8:00AM CDT
The Crohn's & Colitis Foundation of America (CCFA) announces an agreement with Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) to identify and support the potential development and translation of research in the area of inflammatory bowel disease (IBD). Capitalizing on CCFA's expertise in the field of IBD research and CTI's network of academic medical centers, the organizations will collaborate to drive promising translational research projects toward the clinic. The collaboration will initially involve the co-funding of research projects that focus on studying validated targets in Crohn's Disease and ulcerative colitis, which are the two most common types of IBD. This alliance represents CCFA's first-ever joint funding agreement with a pharmaceutical company.

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis(R) (apixaban) at the ESC Congress 2014
Business Wire - Wed Aug 20, 7:00AM CDT
--New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented

Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA.

Pfizer files NDA of Palbociclib with US FDA for breast cancer
M2 - Tue Aug 19, 10:34AM CDT
Healthcare company Pfizer (NYSE FE) revealed on Monday the completion of the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for palbociclib for the treatment of women with advanced or metastatic ER+, HER2- breast cancer.

3 Reasons Pfizer Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 19, 10:01AM CDT
Pfizer , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to...

Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
PR Newswire - Tue Aug 19, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.

Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments

Pfizer (PFE) Breaks Through Resistance at $28.89
Comtex SmarTrend(R) - Mon Aug 18, 11:02AM CDT
Shares of Pfizer (NYSE FE) have bullishly opened above the pivot of $28.65 today and have reached the first resistance level of $28.89. Investors may be interested in a cross of the next upside pivot targets of $29.14 and $29.63.

Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
PRWeb - Mon Aug 18, 8:31AM CDT
The report titled "Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.

Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs" are largely responsible for recognizing and killing cancer cells, but there are some inhibitory mechanisms that interrupt the destruction and prevents cancer cells from being targeted and destroyed.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 128

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 117

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 102

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Texxon Faces Revenue Slide Amid Strategic Shifts

Updated Category News Views 33

Texxon's Strategic Transitions and Financial Headaches Texxon Holding Limited (NASDAQ:NPT) just laid their cards on the table, unveiling a mixed bag in their fiscal year 2026 results. As the world's chemical and plastics scene faces winds of change, Texxon buckled down and tried to steer the ship clear from the rocks. It's a balancing act juggling market headwinds, a new...

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 61

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 114

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 134

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 83

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading
OFRM Faces Legal Heat Over Toddler Snack Recall

Updated Category News Views 122

OFRM Under the Microscope: Who Saw This Coming? Smack dab in the middle of navigating everyday market volatility, here's Once Upon A Farm (NYSE: OFRM) taking the spotlight—but for all the wrong reasons. The company got slapped with a stark FDA warning. Their Tractor Wheels toddler snacks allegedly pose a choking risk— think 'dry, sticky mass' refusing to budge with...

Continue Reading

Top 5 Most Recently Viewed Articles

Axiom Foods Unveils Neutral Pea Protein Amid Market Challenges

Updated Category News Views 292

Revolutionizing the U.S. Pea Protein Market The U.S. pea protein sector is undergoing significant transformations driven by recent tariff regulations. As steep tariffs were imposed on Chinese imports, the challenges in supply chains have heightened. Axiom Foods is stepping up its game to become a key player in the industry by introducing its innovative product,...

Continue Reading
Cabaletta Bio's Transformative Developments in Autoimmunity Therapy

Updated Category News Views 217

Cabaletta Bio's Progress: A Focus on Innovative Therapies Cabaletta Bio, Inc. (Nasdaq: CABA) is making significant strides in the field of biotechnology, particularly in developing targeted cell therapies for autoimmune diseases. It's clear that the company is gearing up for a transformative journey with rese-cel, an investigational therapy designed to reset the immune...

Continue Reading
NBPE Share Buyback: A Strategic Move for Investors

Updated Category News Views 159

NB Private Equity Partners Announces Strategic Share Buyback In a significant turn of events, NB Private Equity Partners has declared its plans for a share buyback, a move that signals confidence in the company's future and aims to enhance shareholder value. This decision follows the recent approval from shareholders, making it an exciting development for investors...

Continue Reading
New Jersey Welcomes New York Plastic Surgical Group's Expansion

Updated Category News Views 253

New York Plastic Surgical Group Expands to New Jersey New York Plastic Surgical Group (NYPS Group), one of the leading plastic surgery practices in the nation, has announced an exciting expansion into New Jersey. The company has opened a new office in Englewood, providing residents with easy access to its comprehensive range of plastic, reconstructive, and aesthetic...

Continue Reading
Huasun Energy Expands Presence with Next2Sun Partnership in PV Tech

Updated Category News Views 416

Huasun Energy and Next2Sun Forge Exclusive Partnership Huasun Energy, recognized globally as the leading producer of heterojunction (HJT) solar products, has entered into an exclusive strategic partnership with Next2Sun, a notable player in vertical solar technology. This collaboration marks an important advancement for the integration of vertical photovoltaic (PV)...

Continue Reading